Drug Profile
UB 311
Alternative Names: Alzheimer's disease vaccine - United Biomedical; Amyloid-beta-1-14-vaccine; UB311; UBITh AD immunotherapeutic vaccineLatest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator United Biomedical
- Class Alzheimer vaccines; Antidementias; Peptide vaccines; Synthetic vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 30 Jan 2024 Vaxxinity and Center for Translational Research in Neurodegenerative Disease (CTRND) enters into a research collaboration agreement to develop immunotherapies to prevent and mitigate neurodegenerative diseases
- 10 Aug 2023 Efficacy data from a phase IIa trial in Alzheimer's disease released by Vaxxinity
- 31 Dec 2022 UB 311 is available for licensing as of 31 May 2022. https://www.sec.gov/ix?doc=/Archives/edgar/data/1851657/000156276223000132/vaxxq410k.htm